When Insys Therapeutics settled with the feds for a whopping $225 million last week on federal kickback charges, the drugmaker hoped it had put its troubled past behind it. Turns out that was only the ...

Insys Therapeutics said it tapped Lazard to advise the drugmaker on its plans to explore strategic options and is in talks to divest its fentanyl sublingual spray Subsys, sending the company's shares ...

Insys advanced money for defense attorneys from Ropes & Gray, Paul Weiss Kapoor served two years in prison after a 2019 conviction Aug 18 (Reuters) - Convicted Insys Therapeutics Inc founder John ...

Topline: Insys Therapeutics, Inc., filed for bankruptcy on Monday, following last week’s $225 million settlement with the federal government over the company’s alleged bribing of doctors to prescribe ...

Over the last two years, much of the healthcare world has been watching the government’s prosecution of Insys Therapeutics for its sales and marketing practices related to its Subsys spray. Subsys is ...

Insys Therapeutics shares tanked Monday after the company said it may have to file for bankruptcy because it can't afford legal costs related to a DOJ investigation. A Boston jury convicted Insys ...

PHOENIX, March 25, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, ...

Two ex-Insys Therapeutics bosses accepted their racketeering sentences in very different ways Tuesday, as a top sales director pledged to immediately appeal his ruling while a regional manager fought ...

John Kapoor, the former CEO of Insys Therapeutics, agreed to pay New Jersey $5 million to settle allegations for his role in fueling the opioid epidemic, New Jersey Attorney General Gurbir Grewal ...

Insys Therapeutics' latest update contained nothing but bad news for investors. The company stated that its available liquidity is down to $87.6 million in cash and cash equivalents as of March 31, ...

The founder of an Arizona pharmaceutical company was ordered to spend 5 1/2 years in prison Thursday for orchestrating a bribery and kickback scheme prosecutors said helped fuel the opioid crisis.

The CEO of Insys Therapeutics has stepped down from as the embattled drugmaker continues to wind down operations under bankruptcy protection, according to The Phoenix Business Journal. Andrew Long ...